- Report
- October 2025
- 376 Pages
Global
From €5232EUR$5,850USD£4,538GBP
- Clinical Trials
- April 2025
- 250 Pages
Global
From €2683EUR$3,000USD£2,327GBP
- Clinical Trials
- April 2025
- 280 Pages
Global
From €2683EUR$3,000USD£2,327GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1118EUR$1,250USD£970GBP
- Report
- December 2024
- 72 Pages
Global
From €3532EUR$3,950USD£3,064GBP
- Report
- February 2025
- 150 Pages
Global
From €2682EUR$2,999USD£2,326GBP
- Report
- March 2025
- 95 Pages
Global
From €3500EUR$4,192USD£3,142GBP
- Report
- September 2025
- 27 Pages
Global
From €5361EUR$5,995USD£4,650GBP
- Clinical Trials
- August 2025
- 551 Pages
Global
From €3085EUR$3,450USD£2,676GBP
- Clinical Trials
- March 2025
- 624 Pages
Global
From €3085EUR$3,450USD£2,676GBP
- Report
- September 2025
- 100 Pages
Global
From €4382EUR$4,900USD£3,801GBP
- Report
- August 2025
- 195 Pages
Global
From €3170EUR$3,545USD£2,750GBP
€3523EUR$3,939USD£3,055GBP
- Report
- February 2025
- 182 Pages
Global
From €4024EUR$4,500USD£3,491GBP
- Report
- October 2025
- 189 Pages
Global
From €3170EUR$3,545USD£2,750GBP
€3523EUR$3,939USD£3,055GBP
- Report
- October 2025
- 181 Pages
Global
From €5232EUR$5,850USD£4,538GBP
- Report
- February 2025
- 200 Pages
Global
From €4015EUR$4,490USD£3,483GBP
- Report
- May 2025
- 110 Pages
Global
From €4248EUR$4,750USD£3,685GBP
- Report
- March 2025
- 150 Pages
Global
From €3443EUR$3,850USD£2,986GBP
€4337EUR$4,850USD£3,762GBP
- Report
- October 2024
- 100 Pages
Global
From €5321EUR$5,950USD£4,615GBP
- Report
- January 2022
- 191 Pages
Global
From €3801EUR$4,250USD£3,297GBP

The Pulmonary Fibrosis Drug market is a subset of the larger Respiratory Drugs market. It is composed of drugs used to treat pulmonary fibrosis, a chronic and progressive lung disease. These drugs are used to reduce symptoms, slow the progression of the disease, and improve quality of life. Common treatments include corticosteroids, immunosuppressants, and antifibrotic agents. In some cases, lung transplantation may be recommended.
The Pulmonary Fibrosis Drug market is highly competitive, with many companies developing and marketing treatments. Some of these companies include Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Novartis, and Vertex Pharmaceuticals. Show Less Read more